Fiserv posts 30 percent quarterly loss
The information management services firm reported net income of $105.9 million, down from the $150.5 million reported in the fourt...Bone Care marks solid quarter on Hectorol sales jump
Hectorol is a Vitamin D-based drug used to lower abnormally high levels of parathyroid hormone in patients with chronic kidney disease. Gross margins run about 75 percent....Merge eFilm announces rapid growth in first quarter
MILWAUKEE -- Merge Technologies Inc. announced Wednesday that its net sales are up 41 percent in first-quarter 2004, compared to first-quarter 2003. The Milwaukee-based company, which does business as RIS Logic's pro...Midwest life science stocks sizzle in a tepid first quarter
The major life scie...CIOs looking to hire more IT workers in second quarter
The report, published after former chairman...Humans are Gobbling Up a Quarter of Nature's Resources, Reveals Study
Humans are gobbling up almost a quarter of nature's resources, according to a new study by a team of Austrian researchers from Klagenfurt University, Vienna. Using UN Food and Agriculture Organisation data on agricultural land use in 161 countries, Helmut Haberl and his colleagues found that increasing consumption of resources by humans was leading to a gradual depletion of species...Allergen, Weed, Lamb's Quarters
Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
MELBOURNE, Australia, May 03, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today that the Companyintends to initiate a Phase 1b clinical trial to demonstrate theefficacy and safety of the improved formulation of its transdermalinsulin product, TPM-02/Insulin, containing long-acting insulin.The trial is expected to commence in the second quarter of2007....